Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Insulet Corporation earns a Q-Score of 67.5/100 from the StockConviction analysis engine. Current valuation zone: Overvalued.
🔒 Estimated value and discount % — Premium account required
Full analysis
Access the full analysis
Estimated value, discount %, detailed conviction signals, history and zone alerts.